A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

NCT00137397 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Incontinence

Interventions

DRUG: Tolterodine ER
DRUG: Placebo

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.